Sound Income Strategies’s Alaunos Therapeutics TCRT Stock Holding History

Sound Income Strategies’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5	Closed	-$87	–	1485
2024 Q1	$87	Buy	+5	New	+$100	﹤0.01%	1305

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Sound Income Strategies's TCRT Position: Q2 2024 in Review

Sound Income Strategies sold out of Alaunos Therapeutics (TCRT) in Q2 2024, closing a stake of 5 shares — an estimated $87 sold.

Sound Income Strategies first reported a position in TCRT in Q1 2024 and held it in 1 quarter. The position peaked at $87 in Q1 2024. 50 funds tracked by Wall St. Rank hold TCRT as of Q2 2024.

Sound Income Strategies reported no remaining Alaunos Therapeutics position as of Q2 2024 after selling out during the quarter.
Sound Income Strategies sold 5 Alaunos Therapeutics shares in Q2 2024, an estimated $87.
Sound Income Strategies first reported a position in Alaunos Therapeutics in Q1 2024 and held it in 1 quarter.
Sound Income Strategies's Alaunos Therapeutics position peaked at $87 in Q1 2024.
50 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2024.

Based on Sound Income Strategies's 13F filing for Q2 2024, filed 12 Jul 2024.